Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Publication year range
1.
Transfus Med ; 17(3): 182-6, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17561859

ABSTRACT

Once thawed, fresh-frozen plasma (FFP) should be used, according to guidelines, within 24 h. In hospital practice, this may be associated with wastage. This study has been performed to investigate the coagulation levels of thawed quarantine FFP as used in the Netherlands. Five units of quarantine FFP, obtained by plasmapheresis, were thawed and by sterile docking divided into satellite bags (SB). SB 2-4 were stored at room temperature (RT) for, respectively, 1, 3 and 6 h and SB 5-9 at 4 degrees C for 6, 12 and 24 h and 1 and 2 weeks. At each time point, activated partial thromboplastin time (APTT), prothrombin time (PT), fibrinogen, factor V (FV), factor VIII (FVIII) and ADAMTS13 activity were measured. During storage at RT for up to 6 h, no major differences were found in the levels of FV, PT, fibrinogen and ADAMTS13 activity. FVIII activity showed a decrease of 16% and the APTT was prolonged by 6%. During storage at 4 degrees C for 2 weeks, FV and FVIII were reduced by 35 and 45%, respectively. The APTT and PT were prolonged by 17 and 15%, respectively. Fibrinogen was decreased by 8%. No change in ADAMTS13 activity was found. FFP stored at RT for 6 h or at 4 degrees C for 2 weeks can provide sufficient support for adequate haemostasis except for patients with a known deficiency for FVIII and can be used for plasmapheresis in patients with thrombotic thrombocytopenic purpura (TTP).


Subject(s)
Blood Coagulation , Plasma/physiology , Factor V/analysis , Factor VIII/analysis , Fibrinogen/analysis , Fibrinolysis , Freezing , Humans , Partial Thromboplastin Time , Prothrombin Time , Temperature , Thromboplastin/analysis
2.
Ned Tijdschr Geneeskd ; 149(21): 1179-83, 2005 May 21.
Article in Dutch | MEDLINE | ID: mdl-15940924

ABSTRACT

Development of communication skills is an important aspect of the training of young physicians. In our hospital, we have developed a programme consisting of monthly 1-hour meetings in which the residents in internal medicine discuss incidents and communication problems with patients or their relatives. During these meetings, residents give feedback to each other under the supervision of the consultation-liaison psychiatrist. Important issues that have been discussed include refusal of treatment by patients, how to handle aggression, how to respond to complaints, relating bad news to patients, euthanasia, and dealing with personal problems or work-related stress. The meeting is well attended and appreciated by the residents. We believe that this approach of improving communication skills based on actual problems encountered in daily practice makes a valuable contribution to the training of young doctors.


Subject(s)
Communication , Internal Medicine/education , Internship and Residency/methods , Physician-Patient Relations , Problem-Based Learning , Adult , Aged , Female , Humans , Male , Middle Aged
3.
Trop Med Int Health ; 5(6): 459-63, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10929148

ABSTRACT

We conducted two randomized clinical trials to determine the in vivo efficacy of amodiaquine and sulfadoxine/pyrimethamine in treating Plasmodium falciparum malaria. Seventy-five patients under the age of 10 years in Kibwezi, Kenya, and 171 patients in Kigoma, Tanzania, were enrolled for treatment. Due to loss of eight patients in Kibwezi and 37 in Kigoma to follow-up, we used best and worst case scenarios for the parasitological response. The in vivo sensitivity of Plasmodium falciparum to amodiaquine was 75% (no loss to follow-up) in Kibwezi and ranged from 85% in the best to 65% in the worst case scenario in Kigoma. The sensitivity to sulfadoxine/pyrimethamine was 70% to 88% in Kibwezi and 65% to 89% in Kigoma. R1 resistance to amodiaquine was 22% in Kibwezi and varied from 6% in the best to 26% for the worst case scenario in Kigoma. The R1 resistance to sulfadoxine/pyrimethamine was 5% to 23% in Kibwezi and 2% to 26% in Kigoma. R2 resistance was 3% for amodiaquine and 7% for sulfadoxine/pyrimethamine in Kibwezi and 9% in Kigoma for each treatment group. There was no statistically significant difference between treatment groups at either study site, except for a slight difference in R1 resistance in the best case scenario, Kibwezi, in favour of S/P. Although both amodiaquine and sulfadoxine/pyrimethamine resistance seems to be increasing, these antimalarials are still effective in parasite clearance.


Subject(s)
Antimalarials/therapeutic use , Malaria, Falciparum/drug therapy , Parasitemia/drug therapy , Amodiaquine/pharmacology , Amodiaquine/therapeutic use , Animals , Antimalarials/pharmacology , Child , Child, Preschool , Drug Resistance, Microbial , Female , Fever , Humans , Infant , Kenya , Male , Plasmodium falciparum/drug effects , Pyrimethamine/pharmacology , Pyrimethamine/therapeutic use , Sulfadoxine/pharmacology , Sulfadoxine/therapeutic use , Tanzania , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL